Regulation of amyloid-beta production by glycosphingolipid synthesis inhibition

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/568651

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Alzheimer's disease (AD) prevalence is rising and there is currently no curative treatment. Production of neurotoxic amyloid-beta peptide (Abeta) in the brain is thought to be one causative factor in AD. We have recently discovered a new drug that alters lipid levels in cell membranes and potently inhibits Abeta production by neurons. We will define precisely how this drug works and examine its potential to reduce Abeta accumulation in the brains of mice genetically engineered to mimic AD.

Funded Activity Details

Start Date: 01-01-2009

End Date: 01-01-2012

Funding Scheme: NHMRC Project Grants

Funding Amount: $549,925.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Medical parasitology

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

Alzheimer's disease | Amyloid-beta peptide | Membrane lipids | Neurodegeneration | Neurodegenerative disease | Stress ageing and accelerated senescence

Related Links